PMID- 16648324
OWN - NLM
STAT- MEDLINE
DCOM- 20060612
LR  - 20220318
IS  - 0002-953X (Print)
IS  - 0002-953X (Linking)
VI  - 163
IP  - 5
DP  - 2006 May
TI  - Aripiprazole in the treatment of patients with borderline personality disorder: a 
      double-blind, placebo-controlled study.
PG  - 833-8
AB  - OBJECTIVE: Aripiprazole is a relatively new atypical antipsychotic agent that has 
      been successfully employed in therapy for schizophrenia and schizoaffective 
      disorders. A few neuroleptics have been used in therapy for patients with 
      borderline personality disorder, which is associated with severe 
      psychopathological symptoms. Aripiprazole, however, has not yet been tested for 
      this disorder, and the goal of this study was to determine whether aripiprazole 
      is effective in the treatment of several domains of symptoms of borderline 
      personality disorder. METHOD: Subjects meeting criteria for the Structured 
      Clinical Interview for DSM-III-R Personality Disorders for borderline personality 
      disorder (43 women and 9 men) were randomly assigned in a 1:1 ratio to 15 mg/day 
      of aripiprazole (N=26) or placebo (N=26) for 8 weeks. Primary outcome measures 
      were changes in scores on the symptom checklist (SCL-90-R), the Hamilton 
      Depression Rating Scale (HAM-D), the Hamilton Anxiety Rating Scale (HAM-A), and 
      the State-Trait Anger Expression Inventory and were assessed weekly. Side effects 
      and self-injury were assessed with a nonvalidated questionnaire. RESULTS: 
      According to the intent-to-treat principle, significant changes in scores on most 
      scales of the SCL-90-R, the HAM-D, the HAM-A, and all scales of the State-Trait 
      Anger Expression Inventory were observed in the subjects treated with 
      aripiprazole after 8 weeks. Self-injury occurred in the groups. The reported side 
      effects were headache, insomnia, nausea, numbness, constipation, and anxiety. 
      CONCLUSIONS: Aripiprazole appears to be a safe and effective agent in the 
      treatment of patients with borderline personality disorder.
FAU - Nickel, Marius K
AU  - Nickel MK
AD  - Clinic for Psychosomatic Medicine, Inntalklinik, 84359 Simbach am Inn, Germany. 
      m.nickel@inntalklinik.de
FAU - Muehlbacher, Moritz
AU  - Muehlbacher M
FAU - Nickel, Cerstin
AU  - Nickel C
FAU - Kettler, Christian
AU  - Kettler C
FAU - Pedrosa Gil, Francisco
AU  - Pedrosa Gil F
FAU - Bachler, Egon
AU  - Bachler E
FAU - Buschmann, Wiebke
AU  - Buschmann W
FAU - Rother, Nadine
AU  - Rother N
FAU - Fartacek, Reinhold
AU  - Fartacek R
FAU - Egger, Christoph
AU  - Egger C
FAU - Anvar, Javaid
AU  - Anvar J
FAU - Rother, Wolfhardt K
AU  - Rother WK
FAU - Loew, Thomas H
AU  - Loew TH
FAU - Kaplan, Patrick
AU  - Kaplan P
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Am J Psychiatry
JT  - The American journal of psychiatry
JID - 0370512
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Piperazines)
RN  - 0 (Placebos)
RN  - 0 (Quinolones)
RN  - 82VFR53I78 (Aripiprazole)
SB  - IM
MH  - Aggression/drug effects
MH  - Anger/drug effects
MH  - Antipsychotic Agents/adverse effects/*therapeutic use
MH  - Aripiprazole
MH  - Borderline Personality Disorder/diagnosis/*drug therapy/psychology
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Personality Inventory
MH  - Piperazines/adverse effects/*therapeutic use
MH  - Placebos
MH  - Psychiatric Status Rating Scales
MH  - Quinolones/adverse effects/*therapeutic use
MH  - Severity of Illness Index
MH  - Suicide/psychology
MH  - Surveys and Questionnaires
MH  - Treatment Outcome
EDAT- 2006/05/02 09:00
MHDA- 2006/06/13 09:00
CRDT- 2006/05/02 09:00
PHST- 2006/05/02 09:00 [pubmed]
PHST- 2006/06/13 09:00 [medline]
PHST- 2006/05/02 09:00 [entrez]
AID - 163/5/833 [pii]
AID - 10.1176/ajp.2006.163.5.833 [doi]
PST - ppublish
SO  - Am J Psychiatry. 2006 May;163(5):833-8. doi: 10.1176/ajp.2006.163.5.833.